KRAS and BRAF Mutational Status can be Accurately Determined on Diagnostic Tissue Biopsies: An Analysis of Matched Biopsy and Resection Material from Patients with Colon Cancer in the NCRI FOxTROT trial

Ítems similars

• Histopathological Downstaging of Colon Cancer Following Six Weeks of Pre-operative Chemotherapy: Early Results of the NCRI FOxTROT Trial
  per: West, N, et al.
  Publicat: (2012)
• FOxTROT: Randomized phase II study of neoadjuvant chemotherapy with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer
  per: Gray, R, et al.
  Publicat: (2010)
• FOxTROT: Randomized phase II study of neoadjuvant chemotherapy (CT) with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer: Planned interim report
  per: Morton, D, et al.
  Publicat: (2011)
• Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing
  per: Susan D. Richman, et al.
  Publicat: (2011-01-01)
• Whiskey Tango Foxtrot: Technological Convergence?
  per: Anne-Laure Mention, et al.
  Publicat: (2018-11-01)